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Background Exercise-stress echocardiography is useful
in management and risk stratiﬁcation of patients with
asymptomatic aortic stenosis (AS). Resting B-type
natriuretic peptide (BNP) level is associated with
increased risk of adverse events. The incremental
prognostic value of BNP response during exercise is
unknown.
Objective The purpose of this study was to assess the
usefulness of plasma level of BNP during exercise to
predict occurrence of events in asymptomatic patients
with severe AS.
Methods Resting and exercise-stress echocardiographic
data and plasma BNP levels were prospectively collected
in 211 asymptomatic AS patients in whom 157 had
severe AS with preserved LVEF in two centres. The study
end-point was the occurrence of death or aortic valve
replacement.
Results Plasma BNP level increased from rest to
exercise (p<0.0001). During a mean follow-up of 1.5
±1.2 years, 87 patients with severe AS reached the
predeﬁned end-point. Higher peak-exercise BNP level
was associated with higher occurrence of adverse events
(p<0.0001). In multivariate analysis, second and third
tertiles of peak-exercise BNP (T2: HR=2.9; p=0.002 and
T3: HR=5.3; p<0.0001, respectively) were powerful
predictors of events compared with the ﬁrst tertile.
Further adjustment for resting BNP provided comparable
results (T2: HR=2.8; p=0.003 and T3: HR=5.0;
p<0.0001). This relationship persisted in both subsets of
patients with low or high resting BNP.
Conclusions This study reports that peak-exercise BNP
level provides signiﬁcant incremental prognostic value
beyond what is achieved by demographic and
echocardiographic data, as well as resting BNP level.
INTRODUCTION
Aortic valve replacement (AVR) is the only efﬁcient
treatment for aortic stenosis (AS). However, the
optimal timing of AVR in asymptomatic patients with
severe AS remains a matter of debate. Both the
American College of Cardiology/American Heart
Association (ACC/AHA) and the European Society of
Cardiology (ESC) guidelines recommend AVR for
patients with severe AS who present with symptoms
or LV systolic dysfunction (ie, LVEF <50%).1 2
Patients with AS are often older, have more comorbid-
ities and are less physically active, which make the
assessment of symptoms challenging and unreliable.3–5
Hence, this raises the concern that a large propor-
tion of these patients with AS could be operated too
late in the course of the disease, which could nega-
tively impact on the outcome.6–8 Previous studies
reported that exercise testing, exercise-stress echo-
cardiography and resting plasma levels of B-type
natriuretic peptide (BNP) can improve risk stratiﬁca-
tion of patients with asymptomatic AS.9–15 The
BNP response to exercise has been shown to be asso-
ciated with outcomes in various cardiovascular dis-
eases.16–19 We hypothesised that plasma level of
BNP after exercise provided incremental prognostic
value beyond what is achieved by demographic,
echocardiographic and resting BNP data.
METHODS
Patient population
We prospectively enrolled 211 asymptomatic
patients with moderate to severe AS (peak aortic
jet velocity >2.5 m/s and aortic valve area (AVA)
<1.5 cm2) and preserved LVEF in two centres
(Quebec, n=40; and Liège, n=171). Patients with
the following criteria were excluded: (i) moderate
to severe aortic regurgitation or mitral valve
disease; (ii) pregnant or lactating women; (iii)
abnormal exercise test as previously deﬁned;12 and
(iv) estimated glomerular ﬁltration rate <60 mL/
min (Modiﬁcation of the Diet in Renal Disease
(MDRD) formula). The study was approved by the
relevant Ethics Committees, and patients signed a
written informed consent.
Clinical data
Clinical data included age, gender, height, weight,
body surface area (BSA), systolic and diastolic
blood pressures, documented diagnoses of hyper-
tension, diabetes, hypercholesterolaemia, and
history of smoking, as previously deﬁned.19
Exercise protocol
A symptom-limited graded bicycle exercise test was
performed in the semisupine position on a dedi-
cated tilting exercise table, following previously
published settings.12
Doppler echocardiographic data
Doppler echocardiographic data were obtained at
rest and at peak-exercise (peak-ex).
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The Doppler echocardiographic indices of AS severity
included peak aortic jet velocity, peak and mean transvalvular
pressure gradients, and AVA indexed to BSA. Severe AS was
deﬁned according to ACC/AHA—ESC guidelines.1 2
The relative wall thickness and LV mass indexed to BSA were
calculated.20 LVEF was measured with the use of biplane
Simpson method.
Left atrial (LA) area was obtained by planimetry at end systole
from apical four-chamber view and was indexed to BSA. E to e0
ratio was calculated from the E-wave of mitral inﬂow and the
average of septal and lateral mitral annulus e0-wave. Systolic pul-
monary arterial pressure (SPAP) was evaluated from the regurgitant
jet of the tricuspid insufﬁciency.12 Resting and exercise pulmonary
hypertension (PHT) were deﬁned as SPAP >50 and >60 mmHg,
respectively. As a measure of global LV haemodynamic load, we cal-
culated the valvulo-arterial impedance (Zva).
21
Plasma BNP level
Venous blood samples for BNP measurements were drawn
before echocardiography after 20 min of supine rest (resting
BNP) and at peak-ex, that is, within the 3 min following the
end of exercise (peak-ex BNP) as previously validated.19
Study end-point
The study end-point was the occurrence of death or AVR moti-
vated by development of symptoms or LV dysfunction (ie, class
I indication). To ensure blinding, both resting and peak-ex BNP
levels were not transmitted to the treating physician or surgeon.
Statistical analysis
Patients were divided into three groups according to tertiles of
peak-ex BNP level. Continuous data were expressed as mean±SD
and were tested for normality of distribution and homogeneity of
variances with the Shapiro–Wilk and Levene tests, respectively.
Groups were compared with one-way Analysis of Variance
(ANOVA) followed by a Tukey’s post hoc test when appropriate.
Categorical data were expressed as percentage and groups were
compared with the χ2 or Fischer’s exact tests when appropriate.
BNP levels were reported as median (IQR) and the natural loga-
rithm transformation was applied to BNP levels. Difference
between resting and peak-ex BNP levels was obtained with paired t
test and correlations between resting BNP and peak-ex BNPor abso-
lute change in BNP (δ BNP) were determined using Pearson’s
product-moment correlations. Multivariate linear regression ana-
lysis, including age, gender, peak-ex workload and exercise-induced
increase in mean gradient, stroke volume index and Zva, was per-
formed to identify the independent determinants of peak-ex BNP
level. Kaplan–Meier curves and log-rank tests of the time-to-event
data were used to assess the effect of tertiles of peak-ex BNP and of
δ BNP on the composite end-point of death or AVR. The relation-
ships among resting, peak-ex, δ BNP levels and event-free survival
were assessed with the use of individual and multivariate Cox
proportional-hazard analyses. The traditional risk factors of the
composite of death or AVR and all variables with p value <0.10 in
individual Cox analysis (ie, age, gender, resting mean gradient,
resting Zva, resting indexed LA area and exercise-induced increase
in heart rate, mean gradient and Zva) were entered in the multivari-
ate Cox model. The proportional-hazards assumption was checked
with the use of Schoenfeld residuals. The incremental predictive
Table 1 Clinical characteristics and exercise capacity data according to tertiles of peak-ex BNP level
Whole Cohort
n=211
Tertile 1 (6–42 pg/mL)
n=71
Tertile 2 (43–91 pg/mL)
n=70
Tertile 3 (92–956 pg/mL)
n=70 p Value†
Clinical data
Age, years 68±11 65±12 69±10* 69±10* 0.03
Male gender, % 64% 63% 66% 63% 0.91
Height, cm 167±8 167±7 168±10 166±8 0.50
Weight, kg 74±13 76±12 76±12 72±13 0.21
Body surface area, m2 1.82±0.18 1.82±0.18 1.83±0.18 1.81±0.19 0.71
Body mass index, kg/m2 26.6±3.7 27.1±3.9 26.8±3.5 26.0±3.6 0.27
Heart rate, beats/min 70±12 71±12 70±10 70±13 0.99
History of hypertension, % 53% 57% 49% 53% 0.65
Systolic blood pressure, mm Hg 141±21 142±24 139±17 142±21 0.71
Diastolic blood pressure, mm Hg 77±11 79±11 74±10* 77±11 0.04
Hypercholesterolaemia, % 46% 48% 43% 47% 0.83
Diabetes, % 14% 13% 12% 17% 0.44
History of smoking, % 27% 24% 31% 28% 0.65
Resting BNP level, pg/mL 43 (24–81) 16 (9–26) 45 (39–60) 101 (76–133) By design
Exercise testing data
Duration, min 9.1±3.1 9.0±2.6 8.9±2.9 9.4±3.6 0.69
Peak-ex workload, watts 99±35 102±38 101±35 94±33 0.35
Peak-ex heart rate, beats/min 120±19 124±20 119±16 118±19 0.13
Percent of predicted maximal
heart rate, %
91±12 92±12 91±11 90±14 0.83
Peak-ex systolic blood pressure, mm Hg 179±23 184±23 177±24 177±22 0.17
Peak-ex diastolic blood pressure, mm Hg 87±14 90±14 85±14 86±13 0.09
Peak-ex BNP level, pg/mL 58 (29–115) 20 (13–30) 59 (53–74) 146 (115–201) By design
Values are mean±SD except for BNP data which are median (IQR).
†p Value of the one-way ANOVA. The following symbols indicate the significance of the Tukey’s post hoc test: *p<0.05 from ‘Tertile 1’.
BNP, B-type natriuretic peptide; Peak-ex, peak-exercise.
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value of peak-ex BNP was assessed by calculating the net reclassiﬁ-
cation improvement (NRI) for 1-year events (death or AVR) using
the NRI & IDI program codes downloaded online (http://www.ucr.
uu.se/en/index.php/ucr-statistics/program-code/
306-nri-and-idi).22 23 Category cut-points were deﬁned as observed
event rate at 1-year (ie, 28%) or tertiles of risk probabilities deter-
mined using the model with established risk factors (ie, <19%,
19%–35%, and ≥35%). Patients were reclassiﬁed according to
1-year predicted probabilities after addition of peak-ex BNP. The
receiver operating characteristic (ROC) curve analyses were per-
formed to determine the accuracy (area under the curve, AUC) as
well as the best cut-point values for resting and peak-ex BNP levels
to predict 1-year events expressed as a binary outcome. Statistical
analyses were done with Stata Software (V.11.0). A p value <0.05
was considered statistically signiﬁcant.
RESULTS
Population characteristics
Baseline characteristics of the population are depicted in tables
1 and 2. Severe AS was present in 157 (74%) patients. The base-
line characteristics (all p>0.05; data not shown) and 1-year
event rates (65% vs 73%; p=0.87) were similar in the subset of
patients enrolled from Canada versus those enrolled from
Belgium.
Response of BNP to exercise
BNP level increased signiﬁcantly from rest to peak-ex
(p<0.0001; ﬁgure 1A) and both resting and peak-ex BNP levels
were strongly correlated (r=0.89, p<0.0001; ﬁgure 1B). The
exercise-induced absolute change in BNP was 9 (2–29) pg/mL
and 182 (86%) patients exhibited an increase in BNP during
exercise (ie, δ BNP>0). There was a signiﬁcant but modest cor-
relation between resting BNP and absolute δ BNP (r=0.31,
p<0.0001; ﬁgure 1C). Peak-ex BNP correlated weakly and
negatively with peak-ex workload (r=−0.16; p=0.03).
Patients in the second (T2) and third (T3) tertiles of peak-ex
BNP had higher resting BNP level (p<0.0001, table 1); they
were signiﬁcantly older (p=0.03, table 1) and had more severe
AS (table 2) compared with patients in the ﬁrst tertile (T1). The
exercise testing data were similar between the three tertiles
(table 1). Resting indexed LA area and Zva were higher in T3
compared with T1 and T2 (table 2).
Correlates of peak-ex BNP
Resting Doppler echocardiographic variables associated with
peak-ex BNP level were mean gradient, indexed LA area and
Zva (table 3). After adjustment for age, gender and peak-ex
workload, as well as for exercise-stress echocardiographic vari-
ables associated with peak-ex BNP level (table 3, Multivariate
Table 2 Resting and peak-exercise echocardiographic data according to tertiles of peak-exercise BNP level
Whole cohort
n=211
Tertile 1 (6–42 pg/mL)
n=71
Tertile 2 (43–91 pg/mL)
n=70





Stroke volume, mL 84±19 86±20 86±19 79±19 0.05
Stroke volume index, mL/m2 46±11 48±11 47±11 44±11 0.13
Peak aortic jet velocity, m/s 4.0±0.7 3.7±0.7 4.1±0.7* 4.1±0.8* 0.001
Peak transvalvular gradient,
mm Hg
66±24 59±21 69±23* 71±25* 0.006
Mean transvalvular gradient,
mm Hg
41±15 37±13 43±15* 43±16* 0.02
Aortic valve area, cm2 0.93±0.21 0.98±0.19 0.90±0.20* 0.90±0.24* 0.03
Indexed aortic valve area, cm2/m2 0.51±0.12 0.54±0.11 0.49±0.10* 0.50±0.13* 0.03
Indexed left atrial area, cm2/m2 11.6±3.3 11.0±3.0 10.9±3.1 12.8±3.4*‡ 0.0007
E to e0 10.8±4.2 9.9±3.9 11.2±3.8 11.4±4.8 0.15
Pulmonary hypertension, % 3% 1% 1% 7% 0.09
Relative wall thickness 0.51±0.12 0.48±011 0.51±0.09 0.54±0.15* 0.04
LV mass index, g/m2 124±45 123±47 126±47 123±41 0.88
LVEF, % 66±7 67±8 66±6 66±8 0.66
Valvulo-arterial imp., mm Hg/
mL m2
4.1±1.1 3.9±0.8 4.0±1.0 4.5±1.3*‡ 0.003
Peak-exercise-stress echocardiographic data
Stroke volume, mL 94±29 91±27 94±32 97±30 0.49
Stroke volume index, mL/m2 49±16 47±15 49±17 50±16 0.49
Peak aortic jet velocity, m/s 4.6±0.8 4.3±0.7 4.7±0.7* 4.7±0.8* 0.01
Peak transvalvular gradient,
mm Hg
86±28 78±27 89±26* 90±30* 0.02
Mean transvalvular gradient,
mm Hg
53±19 48±16 56±18* 56±21* 0.01
Aortic valve area, cm2 1.01±0.29 1.09±0.26 0.97±0.29* 0.98±0.30 0.03
Indexed aortic valve area, cm2/m2 0.56±0.16 0.60±0.15 0.53±0.16* 0.55±0.17 0.03
Pulmonary hypertension, % 32% 23% 34% 39% 0.10
LVEF, % 68±9 68±10 69±8 67±9 0.42
Valvulo-arterial imp., mm Hg/
mL m2
5.1±1.9 5.2±1.8 5.2±1.9 5.0±1.9 0.82
Values are mean±SD.
†p Value of the one-way ANOVA. The following symbols indicate the significance of the Tukey’s post hoc test: *p<0.05 from ‘Tertile 1’; ‡p<0.05 from ‘Tertile 2’.
BNP, B-type natriuretic peptide.
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Model), resting mean gradient (p=0.03), indexed LA area
(p=0.04) and Zva (p=0.009) remained the only variables asso-
ciated with peak-ex BNP level.
Association between resting and peak-ex BNP levels
and outcome
During a mean follow-up of 1.8±1.3 years, 104 prespeciﬁed
events occurred (ie, seven deaths and 97 AVRs) in the whole
cohort. Given that, from a clinical standpoint, the most challen-
ging subset of patients is the one with asymptomatic severe AS,
our analyses of outcomes were focused on this subset and the
results for the whole cohort are presented in online supplemen-
tary table S1 and online supplementary ﬁgures S1 and S2. In the
subset with severe AS (n=157 (74%); mean follow-up: 1.5
±1.2 years), 87 prespeciﬁed events occurred (ie, seven deaths
and 78 AVRs) resulting in a cardiac event-free survival of 72
±4%, 48±5% and 39±5% at 1, 2 and 3 years, respectively.
When using BNP variables in continuous format, both resting
and peak-ex BNP levels were associated with a 1.5-fold increase
in risk of events (for each 100 pg/mL increase) (p<0.0001;
table 4). After adjustment for clinical, resting and exercise-stress
echocardiographic data, resting and peak-ex BNP levels were
associated with a 1.4-fold (p=0.007) and 1.4-fold (p<0.0001)
increase in the risk of events, respectively (table 4, Model #1).
The inclusion of δ BNP in place of peak-ex BNP also provided
similar results (HR=3.4; p<0.0001; table 4, Model #2).
There was a signiﬁcant graded relationship between tertiles of
peak-ex BNP level and occurrence of events (p<0.0001; ﬁgure 2A;
table 4). The analysis of tertiles of δ BNP provided similar results as
tertiles of peak-ex BNP (p<0.0001; ﬁgure 2B; table 4). After multi-
variate adjustment (table 4, Model #1), T2 and T3 of peak-ex BNP
remained associated with signiﬁcant increase in risk of events.
Further adjustment for resting BNP level provided similar results:
tertiles of peak-ex BNP levels were associated with increased risk of
events, whereas resting BNP was not (table 4, Model #2).
Additional adjustment for exercise PHT or exercise workload did
not change the results. The multivariate analysis including resting
BNP expressed in tertiles and peak-ex BNP in continuous variable
was consistent with results presented above (see online supplemen-
tary table S2). Furthermore, when we included both resting and
peak-ex BNPs in continuous format into the multivariate model,
peak-ex BNP remained signiﬁcantly associated with higher risk of
events (HR=3.4; p<0.0001), whereas resting BNP did not.
Incremental prognostic value of peak-ex BNP
The analysis of the effect of peak-ex BNP according to median
value of resting BNP (ie, resting BNP level > or ≤48 pg/mL)
showed that high peak-ex BNP, dichotomised to median value in
both subsets of resting BNP level (ie, > or ≤38 pg/mL in
patients with low resting BNP, and > or ≤120 pg/mL in patients
with high resting BNP), was associated with signiﬁcantly higher
Figure 1 Distribution and association among resting, peak-exercise
and δ B-type natriuretic peptide (BNP) levels in the whole cohort
(n=211). (A) Shows comparison between resting and peak-exercise BNP
levels; the box shows 25th and 75th percentiles, the median line on
the box shows the median value, and error bars the 10th and 90th
percentiles; circles are outliers; the numbers of the top of the graph are
median (IQR) value of BNP levels. (B) Shows correlation between ln
resting BNP and ln peak-exercise BNP level. (C) Shows correlation
between ln resting BNP and absolute δ of BNP levels; r and p value are
from Pearson’s product-moment correlations; several data point were
superimposed; the formula represents the equation of the regression
line.




β coeff.±SE p Value β coeff.±SE p Value
Resting mean transvalvular
gradient, mm Hg
0.25±0.004 0.0003 0.16±0.005 0.03
Resting indexed left atrial area,
cm2/m2
0.23±0.02 0.001 0.15±0.02 0.04
Resting valvulo-arterial
impedance, mm Hg/mL m2
0.25±0.06 0.0002 0.20±0.07 0.009
*Multivariate model included age, gender, peak-exercise workload, and
exercise-induced increase in heart rate, mean transvalvular gradient and
valvulo-arterial impedance. β coeff. is the standardised regression coefficient±SE.
BNP, B-type natriuretic peptide.
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rate of events in both subsets of resting BNP level (p<0.0001;
ﬁgure 3). Among patients with resting BNP level ≤48 pg/mL,
peak-ex BNP>38 pg/mL was associated with signiﬁcantly higher
risk of events (HR=3.1, 95% CI 1.2 to 7.0, p=0.02) after
adjustment for age, gender, mean gradient, indexed LA area,
and exercise-induced increase in heart rate and mean gradient.
The addition of peak-ex BNP level in the multivariate model
including resting BNP (Model #2, table 4) signiﬁcantly
improved the predictive value of the model: the two-category
NRI for 1-year events was 0.17 (95% CI 0.02 to 0.33; p=0.03)
and the three-category NRI was 0.25 (95% CI 0.04 to 0.46;
p=0.02) (see online supplementary tables S3 and S4).
Furthermore, in the ROC curve analyses, the AUC to predict
1-year events was higher with peak-ex BNP compared with
resting BNP (73±5 vs 61±5%; p<0.0001). The best cut-point
value was 86 pg/mL for peak-ex BNP and 58 pg/mL for resting
BNP. In multivariate Cox analysis, peak-ex BNP level >86 pg/
mL was signiﬁcantly associated with increased risk of events
(HR=3.5; p=0.01) whereas resting BNP >58 pg/mL was not
(HR=1.1; p=0.86) (see online supplementary table S5).
DISCUSSION
The main ﬁndings of this study are: (1) Peak-ex BNP is a power-
ful predictor of outcome and provides important incremental
prognostic value beyond what is achieved by demographic, and
echocardiographic data, as well as resting BNP level. (2) This
relationship remains signiﬁcant in the subsets of patients with
low resting BNP.
BNP response to exercise
Resting blood level of BNP is increased in various cardiac dis-
eases as compared with healthy subjects and is associated with
higher LV pressure or volume overload.24 In patients with AS,
resting BNP level is useful to enhance risk stratiﬁcation in AS
patients.13–15 24 25 In response to exercise, BNP level may
increase both in normal healthy subjects26 and patients with
cardiovascular diseases.16–19 In the present study of asymptom-
atic AS patients, we showed a signiﬁcant increase in BNP during
exercise. The overall correlation between resting and peak-ex
BNP levels was strong but with important inter-individual vari-
ability in the BNP response to exercise; that is, some patients
with low resting level of BNP had marked increase in BNP
during exercise, whereas others had no signiﬁcant change. Large
increase in BNP during exercise may be a surrogate marker for
the adverse repercussions of the haemodynamic burden as well
as of the concomitant diseases on the cardiac chambers and may
therefore help to identify patients who are at a more advanced
stage of the disease at the valvular, arterial and/or ventricular
levels. This hypothesis is supported by the independent associ-
ation we found between peak-ex BNP level and (i) resting AS
severity, (ii) global (valvulo-arterial) LV haemodynamic burden
and (iii) LA enlargement.
Peak-ex BNP and outcome
In this large bi-centric prospective series of patients, peak-ex
BNP level was signiﬁcantly associated with higher risk of events,
even after adjustment for clinical, resting and peak-ex echocar-
diographic data and resting BNP level. The results of multivari-
ate analyses clearly demonstrated that peak-ex BNP provides
incremental prognostic value beyond clinical and resting vari-
ables. Furthermore, this incremental value was also observed in
the subset of patients with low BNP at rest. Hence, peak-ex
BNP allows the cardiologist to re-stratify patients who would be
identiﬁed as low risk otherwise.
Clinical implications
The present ﬁndings suggest that measurement of BNP during
exercise testing or exercise-stress echocardiography may be
useful to enhance risk stratiﬁcation and thus the clinical manage-
ment of asymptomatic patients with severe AS. Patients exhibit-
ing a marked increase in BNP during exercise are at much
higher risk for adverse events in the short-term and thus require
Table 4 Impact of BNP level on event-free survival in patients with severe AS (n=157)
Individual Multivariate models #1 Multivariate models #2
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Resting BNP level
Resting BNP level (per 100 pg/mL increase) 1.5 (1.2 to 1.8) <0.0001 1.4 (1.1 to 1.8) 0.007 – –
Peak-exercise BNP level
Peak-exercise BNP level (per 100 pg/mL increase) 1.5 (1.4 to 1.7) <0.0001 1.4 (1.2 to 1.7) <0.0001 – –
Tertiles of peak-exercise BNP level*
Tertile 1 (6 to 46 pg/mL) 1.0 (referent) – 1.0 (referent) – 1.0 (referent) –
Tertile 2 (47 to 94 pg/mL) 2.6 (1.4 to 5.0) 0.0003 2.9 (1.5 to 5.7) 0.002 2.8 (1.4 to 5.7) 0.003
Tertile 3 (95 to 956 pg/mL) 6.1 (3.2 to 11.4) <0.0001 5.3 (2.6 to 10.8) <0.0001 5.0 (2.3 to 11.0) <0.0001
Resting BNP level (per 100 pg/mL increase) 1.5 (1.2 to 1.8) <0.0001 – – 1.1 (0.7 to 1.5) 0.75
δ Of BNP levels
Absolute difference of BNP levels (per 100 pg/mL increase from rest) 3.6 (2.6 to 4.9) <0.0001 – – 3.4 (2.2 to 5.3) <0.0001
Resting BNP level (per 100 pg/mL increase) 1.5 (1.2 to 1.8) <0.0001 – – 1.0 (0.7 to 1.3) 0.95
Tertiles of δ BNP levels
Tertile 1 (−54 to 4) 1.0 (referent) – 1.0 (referent) – 1.0 (referent) –
Tertile 2 (4 to 20) 2.5 (1.3 to 5.7) 0.0006 3.1 (1.4 to 6.9) 0.006 3.0 (1.2 to 6.2) 0.008
Tertile 3 (20 to 337) 8.4 (4.1 to 17.1) <0.0001 7.7 (3.4 to 17.4) <0.0001 7.1 (3.1 to 16.1) <0.0001
Resting BNP level (per 100 pg/mL increase) 1.5 (1.2 to 1.8) <0.0001 – – 1.2 (0.9 to 1.6) 0.12
Models #1 included age, gender, mean transvalvular gradient, valvulo-arterial impedance, indexed left atrial area, and exercise-induced increases in heart rate, mean transvalvular
gradient, and valvulo-arterial impedance; Models #2 were Models #1 plus resting BNP level.
*The boundaries of the peak-exercise BNP tertiles in the severe AS are slightly different from those in the whole cohort presented in tables 1 and 2.
AS, aortic stenosis; BNP, B-type natriuretic peptide.
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more frequent and closer clinical and echocardiographic
follow-up.
However, BNP levels measured at rest or during exercise are
not speciﬁc to AS severity alone but rather reﬂect the total
burden of disease(s) on the LVand other cardiac chambers. They
should thus be interpreted in light of the parameters more specif-
ically reﬂecting AS severity as well as arterial and global loads.
It is often technically difﬁcult to obtain valid exercise haemo-
dynamic data in all patients, and a circulating biomarker such as
BNP could thus be highly valuable in this context. The measure-
ment of BNP indeed has the advantage of being easy, fast and
reproducible and it can be combined with exercise-stress echo-
cardiography or with standard treadmill exercise test. Further
studies are, however, needed to determine if the present ﬁndings
obtained in the semisupine position can be transposed to the
setting of upright exercise test.
Strengths and limitations
The primary end-point was deﬁned as the composite of AVR
and death and was, in large part, driven by the former event
(87 AVRs and seven deaths in the severe AS subset). AVR may
be inﬂuenced by physician’s perception and interpretation of
disease severity and patient’s symptomatic status. However, this
study included only patients who were ‘truly’ asymptomatic at
baseline (ie, with normal exercise test). The treating physicians
were blinded to BNP data and only AVR motivated by the devel-
opment of symptoms or LV systolic dysfunction was classiﬁed as
event in the composite end-point. Furthermore, all multivariate
models were adjusted for the baseline stenosis severity (ie, mean
gradient at rest and during exercise) and peak-ex BNP remained
an independent predictor of events despite this adjustment.
Figure 3 Comparison of the event-free survival curves for median
peak-exercise B-type natriuretic peptide (BNP) level in the subsets of
patients with high and low resting BNP level in patients with severe
aortic stenosis (n=157). This ﬁgure shows the event-free survival curves
for the composite end-point of death or aortic valve replacement in the
subsets of patients with low versus high resting BNP level (red vs blue
curves, respectively), according to low versus high peak-exercise BNP
(full vs dotted lines, respectively). The symbols indicate the signiﬁcant
difference between groups: *p<0.05 versus ‘Low resting—Low
peak-exercise BNP level’; ¶p<0.05 versus ‘Low resting—High
peak-exercise BNP level’; §p<0.05 versus ‘High resting—Low
peak-exercise BNP level’. The numbers at the bottom of the graph
represent the number of patients at risk at each follow-up year. The p
value is that of the log-rank test.
Figure 2 Comparison of the event-free survival curves for tertiles of
peak-exercise B-type natriuretic peptide (BNP) level and tertiles of δ
BNP levels in patients with severe aortic stenosis (AS) (n=157). This
ﬁgure shows the event-free survival curves for the composite end-point
of death or aortic valve replacement in patients with severe AS (n=157)
according to tertiles of peak-exercise BNP level (A) and tertiles of δ
BNP levels (B). The symbols indicate the signiﬁcant differences between
groups: *p<0.05 versus ‘Tertile 1’; ¶p<0.05 versus ‘Tertile 2’. The
numbers at the bottom of the graph represent the number of patients
at risk at each follow-up year. The p value is that of the log-rank test.
Key messages
What is known on this subject?
Some studies have reported that dosage of resting plasma
B-type natriuretic peptide (BNP), exercise testing and
exercise-stress echocardiography may be useful to predict
outcomes and therefore improve risk stratiﬁcation of patients
with asymptomatic aortic stenosis (AS).
What might this study add?
The results of this study suggest that BNP measured at
peak-exercise provides signiﬁcant incremental prognostic value
beyond what is achieved by demographic data, resting and
exercise echocardiographic data, as well as resting BNP level.
These ﬁndings provide strong impetus for systematic
measurement of BNP during exercise test in the AS population.
How might this impact on clinical practice?
The ﬁndings of this study suggest that asymptomatic patients
with severe AS who display a marked increase in BNP during
exercise could be at higher risk of events. Measurement of BNP
during exercise may thus be useful to enhance risk stratiﬁcation
and adjust the timing of clinical and echocardiographic
follow-up in these patients.
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There were not enough patients to perform a separate analysis
of mortality.
Due to the variability of the cut-off values of BNP reported
in the literature to predict outcomes, we elected to use continu-
ous variables or tertiles of BNP. Given the graded increase in the
risk of adverse events reported in the present study, it would be
misleading to propose a precise cut-point value for the predic-
tion of outcome.
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